Management of atopic dermatitis: Nonadherence to topical therapies in treatment of skin disease and the use of calcineurin inhibitors in difficult eczema

British Journal of Dermatology

Volumn 161, Issue 2, 2009, Pages 219-220

  Anstey, A ^a  

^a ROYAL GWENT HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN; IMMUNOSUPPRESSIVE AGENT;

ATOPIC DERMATITIS; DRUG ANTAGONISM; ECZEMA; HUMAN; NOTE; PATIENT COMPLIANCE; PSYCHOLOGICAL ASPECT; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; CALCINEURIN; DERMATITIS, ATOPIC; ECZEMA; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MEDICATION ADHERENCE;

EID: 73349095043     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2009.09218.x     Document Type: Editorial

References (13)

1. Krejci-Manwaring J, Tusa MG, Carroll C et al. Stealth monitoring of adherence to topical medication: adherence is very poor in children with atopic dermatitis. J Am Acad Dermatol 2007; 56:211-16.
2. Rao VU, Apter AJ. Steroid phobia and adherence -problems, solutions, impact on benefit?risk profile. Immunol Allergy Clin North Am 2005; 25:581-95.
3. Charman CR, Morris AD, Williams HC. Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol 2000; 142:931-6.
4. Hoare C, Li WanPo A, Williams H. Systematic review of treatments for atopic eczema. Health Technol Assess 2000; 4:1-191.
5. Green C, Colquitt JL, Kirby J, Davidson P. Topical corticosteroids for atopic eczema: clinical and cost effectiveness of once-daily vs. more frequent use. Br J Dermatol 2005; 152:130-41.
6. Gupta G, Mallefet P, Kress D, Sergeant A. Adherence to topical dermatological therapy. Lessons from oral drug treatment. Br J Dermatol 2009; 161:221-7.
7. Kripalani S, Yao X, Haynes RB. Interventions to enhance medication adherence in chronic medical conditions: a systematic review. Arch Intern Med 2007; 167:540-50.
8. Ehlers A, Stangier U, Gieler U. Treatment of atopic dermatitis. A comparison of psychological and dermatological approaches to relapse prevention. J Consult Clin Psychol 1995; 3:624-35.
9. Buttgereit F, Burmester GR, Lipworth BJ. Optimised glucocorticoid therapy; the sharpening of an old spear. Lancet 2005; 365:801-3.
10. Rustin MHA. The safety of tacrolimus ointment for the treatment of atopic dermatitis: a review. Br J Dermatol 2007; 157:861-73.
11. Leung DYM, Hanifin JM, Pariser DM et al. Effects of pimecrolimus cream 1% in the treatment of patients with atopic dermatitis who demonstrate a clinical insensitivity to topical corticosteroids; a randomized multi-centre, vehicle-controlled trial. Br J Dermatol 2009; 161:435-43.
12. Li LB, Goleva E, Hall CF et al. Superantigen-induced corticosteroid resistance of human T cells occurs through activation of the mitogen-activated protein kinase kinase?extracellular signal-regulated kinase (MEK?ERK) pathway. J Allergy Clin Immunol 2004; 114:1059-69.
13. Doss N, Reitamo S, Dubertret L et al. Superiority of tacrolimus 0.1% ointment compared with fluticasone 0.005% in adults with moderate to severe atopic dermatitis of the face: results from a randomized, double-blind trial. Br J Dermatol 2009; 161:427-34.